Leukemia research最新文献_第10页

Phytostilbenes in lymphoma: Focuses on the mechanistic and clinical prospects of resveratrol, pterostilbene, piceatannol, and pinosylvin 淋巴瘤中的植物芪：聚焦白藜芦醇、紫檀芪、皮杉醇和红松素的机理和临床前景

IF 2.7 4区医学

Leukemia research Pub Date : 2024-03-01 DOI: 10.1016/j.leukres.2024.107464

Pouya Goleij , Pantea Majma Sanaye , Mehregan Babamohamadi , Mohammad Amin Khazeei Tabari , Roshanak Amirian , Aryan Rezaee , Hamed Mirzaei , Alan Prem Kumar , Gautam Sethi , Sarvin Sadreddini , Philippe Jeandet , Haroon Khan

{"title":"Phytostilbenes in lymphoma: Focuses on the mechanistic and clinical prospects of resveratrol, pterostilbene, piceatannol, and pinosylvin","authors":"Pouya Goleij , Pantea Majma Sanaye , Mehregan Babamohamadi , Mohammad Amin Khazeei Tabari , Roshanak Amirian , Aryan Rezaee , Hamed Mirzaei , Alan Prem Kumar , Gautam Sethi , Sarvin Sadreddini , Philippe Jeandet , Haroon Khan","doi":"10.1016/j.leukres.2024.107464","DOIUrl":"10.1016/j.leukres.2024.107464","url":null,"abstract":"<div><p>Lymphoma is a cancer affecting the lymphatic system that fights infections and diseases. In addition to surgery, radiotherapy, and chemotherapy, novel approaches have recently been investigated, such as phytostilbenes in treating lymphoma. Phytostilbenes are natural compounds present in various plants and have been shown to have different therapeutic effects, including anticancer properties. Resveratrol is a main phytostilbene with various derivates followed by pterostilbene and piceatannol. Studies have revealed that phytostilbenes can suppress the growth and proliferation of lymphoma cells by inducing apoptosis and inhibiting specific enzyme activity in cancer cell survival. The compounds also have antiinflammatory effects contributing to reducing lymphoma-associated inflammation. Additionally, phytostilbenes have been shown to increase the immune system's ability to fight cancer cells by activating immune cells (T-cells and natural killer cells). This review investigates the potential therapeutic effects of phytostilbenes, including resveratrol, pterostilbene, piceatannol, and pinosylvin, against lymphoma.</p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"138 ","pages":"Article 107464"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139977342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia 在核心结合因子急性髓性白血病强化诱导化疗中加入单剂量吉妥珠单抗-奥佐加米星

IF 2.7 4区医学

Leukemia research Pub Date : 2024-02-28 DOI: 10.1016/j.leukres.2024.107467

Garrett Bourne , Kendall Diebold , Manuel Espinoza-Gutarra , Zaid Al-Kadhimi , Kimo Bachiashvili , Sravanti Rangaraju , Pankit Vachhani , Ravi Bhatia , Omer Jamy

{"title":"Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia","authors":"Garrett Bourne , Kendall Diebold , Manuel Espinoza-Gutarra , Zaid Al-Kadhimi , Kimo Bachiashvili , Sravanti Rangaraju , Pankit Vachhani , Ravi Bhatia , Omer Jamy","doi":"10.1016/j.leukres.2024.107467","DOIUrl":"10.1016/j.leukres.2024.107467","url":null,"abstract":"<div><p>In a meta-analysis of 5 trials, the addition of gemtuzumab ozogamicin (GO) to intensive induction chemotherapy led to a survival benefit in patients with core-binding factor (CBF) acute myeloid leukemia (AML). Given the heterogeneous incorporation of GO in clinical trials, the ideal dose and schedule remains unclear. We conducted a single-center retrospective analysis to compare outcomes of patients with CBF-AML treated with intensive induction chemotherapy, with or without a single dose of GO 3 mg/m<sup>2</sup>, during induction only. We included 87 patients (GO=32, control=55). The composite complete remission (cCR) rate was higher in the control group (93%) compared to the GO group (82%) (p<0.001). The rate of measurable residual disease (MRD) negative cCR, by flow cytometry, was similar between both groups. There were no significant differences between the two groups in terms of toxicity. The 3-year relapse-free survival (RFS) for both groups was similar (71% vs 68%, p=0.5). The 3-year overall survival (OS) for the GO group was 68%, compared to 66% for the control group (p=0.9).In multivariable analysis, age and MRD positive status were risk factors for inferior outcomes. We find that survival of patients with CBF-AML is favorable in the real-world setting. The addition of single-dose GO, during induction, did not lead to a higher remission rate or survival benefit, when compared to intensive chemotherapy without GO. Further investigation into the incorporation of GO in the treatment algorithm for CBF-AML is needed.</p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"139 ","pages":"Article 107467"},"PeriodicalIF":2.7,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140033095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia 米托蒽醌、依托泊苷和阿糖胞苷治疗复发性或难治性急性髓性白血病的疗效和安全性

IF 2.7 4区医学

Leukemia research Pub Date : 2024-02-27 DOI: 10.1016/j.leukres.2024.107468

Sharon Zhong , Heena Kurish , Robert Walchack , Hong Li , Jessi Edwards , Abhay Singh , Anjali Advani

{"title":"Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia","authors":"Sharon Zhong , Heena Kurish , Robert Walchack , Hong Li , Jessi Edwards , Abhay Singh , Anjali Advani","doi":"10.1016/j.leukres.2024.107468","DOIUrl":"10.1016/j.leukres.2024.107468","url":null,"abstract":"<div><h3>Background/rationale</h3><p>Most patients with acute myeloid leukemia (AML) develop relapsed or refractory (R/R) disease after receiving initial induction chemotherapy. Salvage chemotherapy followed by allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only curative therapy for R/R AML. Mitoxantrone, etoposide, and cytarabine (MEC) is the current standard of care salvage regimen for R/R AML at Cleveland Clinic. The primary objective was to determine the overall remission rate (ORR: defined as patients achieving complete remission (CR) or complete remission with incomplete hematologic recovery (CRi)) in R/R AML patients who received MEC.</p></div><div><h3>Methods</h3><p>Adult patients with R/R AML treated with MEC between July 1, 2014 and September 30, 2022 were included. ORR and its association with baseline characteristics were determined. Secondary outcomes included overall survival (OS), event-free survival (EFS), relapse-free survival (RFS), and safety.</p></div><div><h3>Results</h3><p>Sixty patients were evaluated. The ORR was 51.7% (33.3% CR and 18.3% CRi). The median time from receipt of MEC to CR/CRi was 7.7 weeks. Patients with bone marrow blasts ≤20% and peripheral blood blasts ≤30% at MEC initiation were more than twice as likely to achieve CR/CRi compared to those with a higher blast burden. The median OS was 6.3 months. Twenty-four (40.0%) patients proceeded to alloHSCT. Twenty-one (35.0%) patients were transferred to the intensive care unit (ICU) during their admission.</p></div><div><h3>Conclusions</h3><p>MEC is an effective salvage regimen for patients with R/R AML, especially among those with low disease burden at initiation. Febrile neutropenia, infections, and severe oral mucositis were common with MEC administration.</p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"139 ","pages":"Article 107468"},"PeriodicalIF":2.7,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140032951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adipose tissue indices predict prognosis in hodgkin lymphoma 预测霍奇金淋巴瘤预后的脂肪组织指数

IF 2.7 4区医学

Leukemia research Pub Date : 2024-02-15 DOI: 10.1016/j.leukres.2024.107457

Demircan Özbalcı , Mehmet Erdoğan , Emine Güçhan Alanoğlu , Sevim Süreyya Şengül , Kamuran Yüceer , Hande Nur Eroğlu , Samet Yağcı

{"title":"Adipose tissue indices predict prognosis in hodgkin lymphoma","authors":"Demircan Özbalcı , Mehmet Erdoğan , Emine Güçhan Alanoğlu , Sevim Süreyya Şengül , Kamuran Yüceer , Hande Nur Eroğlu , Samet Yağcı","doi":"10.1016/j.leukres.2024.107457","DOIUrl":"10.1016/j.leukres.2024.107457","url":null,"abstract":"<div><h3>Introduction background</h3><p>This study evaluated the impact of adipose tissue indices on prognosis of HL.</p></div><div><h3>Methods</h3><p>Fifty-five patients with newly diagnosed Hodgkin Lymphoma were evaluated retrospectively for association with adipose tissue indices (total abdominal tissue volume, radiodensity, subcutaneous and visceral adipose tissue SUVmax value and prognostic factors for Hodgkin Lymphoma such as IPS-3, IPS-7, stage, sedimentation, progression free and overall survival.</p></div><div><h3>Results</h3><p>For IPS-3, SAT SUVmax and TAAT radiodensity were significantly increased in high-risk patients (2and 3) compared to group 0 and 1. For IPS-7, total abdominal adipose volume was significantly decreased in high-risk patients, SAT SUVmax significantly increased in high-risk patients and decreased in low-risk patients. In addition, SAT SUVmax was significantly increased in patients with high sedimentation rate, with B symptoms and who passed away during follow-up. SAT SUVmax showed moderate positive correlation with sedimentation, IPS-3, IPS-7, and stage. In addition, it was observed that TAAT radiodensity and SAT SUVmax were significantly better for determining prognosis than other adipose tissue indices. Roc analysis showed that the diagnostic value of all adipose tissue indices in predicting IPS-3 and IPS-7 prognoses were statistically significant.</p></div><div><h3>Conclusion</h3><p>SAT SUVmax and TAAT radiodensity were two new and independent markers with diagnostic value in predicting prognosis.</p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"138 ","pages":"Article 107457"},"PeriodicalIF":2.7,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139889352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bortezomib modulated the autophagy-lysosomal pathway in a TFEB-dependent manner in multiple myeloma 硼替佐米以 TFEB 依赖性方式调节多发性骨髓瘤的自噬-溶酶体通路

IF 2.7 4区医学

Leukemia research Pub Date : 2024-02-12 DOI: 10.1016/j.leukres.2024.107455

Rongjuan Zhang , Xinhong Yang , Xiaomin Shi , Enhong Xing , Lihong Wang , Changlai Hao , Zhihua Zhang

{"title":"Bortezomib modulated the autophagy-lysosomal pathway in a TFEB-dependent manner in multiple myeloma","authors":"Rongjuan Zhang , Xinhong Yang , Xiaomin Shi , Enhong Xing , Lihong Wang , Changlai Hao , Zhihua Zhang","doi":"10.1016/j.leukres.2024.107455","DOIUrl":"10.1016/j.leukres.2024.107455","url":null,"abstract":"<div><h3>Objective</h3><p>To explore the involvement of TFEB-mediated autophagy-lysosomal mechanisms in multiple myeloma (MM) during bortezomib treatment.</p></div><div><h3>Methods</h3><p>MM cells were exposed to bortezomib or subjected to TFEB knockdown. CCK assay was used to assess the cell proliferation. Western blotting and fluorescent staining were conducted to examine autophagy and lysosomes. The TFEB expression pattern was analyzed, and whole transcriptome sequencing was carried out. Additionally, TFEB target genes were predicted using the GTRD(http://gtrd.biouml.org/) website, and pathway analysis was performed.</p></div><div><h3>Results</h3><p>Bortezomib demonstrated a dose-dependent and time dependent inhibition of cell proliferation. In MM cells treated with bortezomib, LC3B, Beclin-1, TFEB, and Lamp1 exhibited upregulation in a time- and concentration-dependent manner. LysoTracker dye labeling showed an increase in lysosomes in the bortezomib-treated group. Moreover, bortezomib elevated the expression of lysosome-associated factor Lamp1. Bortezomib promoted the nuclear translocation of TFEB, leading to decreased cytoplasmic TFEB and increased nuclear TFEB. TFEB gene silencing reversed bortezomib's inhibitory effect on MM cell lines, significantly reducing autophagosome expression and lysosome numbers. Furthermore, bioinformatic analysis identified the MAPK pathway as a potential downstream target of TFEB.</p></div><div><h3>Conclusion</h3><p>Bortezomib effectively inhibits MM cell proliferation and induces autophagy, partly through TFEB-mediated mechanisms, with potential involvement of the MAPK pathway.</p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"138 ","pages":"Article 107455"},"PeriodicalIF":2.7,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139829517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation 慢性髓性白血病继发性融合的出现是酪氨酸激酶抑制剂耐药性和暴发性危机转化的驱动因素

IF 2.7 4区医学

Leukemia research Pub Date : 2024-02-01 DOI: 10.1016/j.leukres.2024.107439

Lara Boucher, Laura Rozalska, Nathalie Sorel, Gaëlle Olivier, Maria Pilar Gallego Hernanz, Emilie Cayssials, Anna Raimbault, Jean-Claude Chomel

引用次数: 0

Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope 骨髓增生异常肿瘤从遗传性骨髓衰竭综合征/基因易感性综合征演变而来：回到显微镜下

IF 2.7 4区医学

Leukemia research Pub Date : 2024-02-01 DOI: 10.1016/j.leukres.2024.107441

M. Tarek Elghetany , Mrinal M. Patnaik , Joseph D. Khoury

引用次数: 0

Systematic review and meta-analysis evaluating clinical outcomes in adult acute myeloid leukemia patients with central nervous system involvement 评估中枢神经系统受累的成人急性髓性白血病患者临床疗效的系统综述和荟萃分析

IF 2.7 4区医学

Leukemia research Pub Date : 2024-02-01 DOI: 10.1016/j.leukres.2024.107452

Hannah Goulart , Dahniel Sastow , Erin Moshier , Lily Martin , John Mascarenhas , Douglas Tremblay

{"title":"Systematic review and meta-analysis evaluating clinical outcomes in adult acute myeloid leukemia patients with central nervous system involvement","authors":"Hannah Goulart , Dahniel Sastow , Erin Moshier , Lily Martin , John Mascarenhas , Douglas Tremblay","doi":"10.1016/j.leukres.2024.107452","DOIUrl":"https://doi.org/10.1016/j.leukres.2024.107452","url":null,"abstract":"<div><p>Patients with acute myeloid leukemia (AML) may experience extramedullary involvement when disease is present outside of the blood and bone marrow. In particular, the presence of central nervous system (CNS) involvement has traditionally been thought of as a poor prognostic factor. In the presently available literature, there is a paucity of conclusive data surrounding CNS AML given its rarity and lack of unified screening practices. Thus, we performed a systematic review and meta-analysis in order to more definitively characterize survival outcomes in this patient population. In this meta-analysis, we evaluated survival outcomes and response rates from clinical studies on patients with AML stratified by the presence of CNS involvement. Twelve studies were included in the meta-analysis with a resulting hazard ratio (HR) for overall survival (OS) of 1.34 with a 95 % CI of 1.14 to 1.58. These findings suggest that CNS involvement in adult patients with AML is associated with an increased hazard of mortality compared to those patients without CNS involvement. As such, CNS involvement should be viewed as negative prognostic marker, and attention should be made to ensure prompt identification and treatment of patients who experience this complication.</p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"137 ","pages":"Article 107452"},"PeriodicalIF":2.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139709733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phase 2 trial of induction with dasatinib and consolidation with hyper-CVAD plus dasatinib followed by allografting for Ph-positive acute lymphoblastic leukemia in adults 用达沙替尼诱导和超CVAD加达沙替尼巩固治疗成人Ph阳性急性淋巴细胞白血病并进行异体移植的2期试验

IF 2.7 4区医学

Leukemia research Pub Date : 2024-02-01 DOI: 10.1016/j.leukres.2024.107438

Iekuni Oh, Kaoru Hatano, Takashi Ikeda, Yumiko Toda, Daisuke Minakata, Shinichiro Kawaguchi, Kaoru Morita, Chihiro Yamamoto, Masahiro Ashizawa, Kazuya Sato, Kazuaki Kameda, Ayumi Gomyo, Yukiko Misaki, Shunto Kawamura, Shunichi Kimura, Hiroyuki Kobayashi, Hiroyuki Sato, Hideki Nakasone, Ken Ohmine, Shinichiro Fujiwara, Yoshinobu Kanda

引用次数: 0

Circ_0005615 enhances multiple myeloma progression through interaction with EIF4A3 to regulate MAP3K4 m6A modification mediated by ALKBH5 Circ_0005615 通过与 EIF4A3 相互作用来调控 ALKBH5 介导的 MAP3K4 m6A 修饰，从而促进多发性骨髓瘤的进展

IF 2.7 4区医学

Leukemia research Pub Date : 2024-02-01 DOI: 10.1016/j.leukres.2024.107451

Kai Zhu , Fengquan Gou , Ziwen Zhao , Ke Xu , Jian Song , Hongyi Jiang , Feng Zhang , Yanli Yang , Jiajia Li

{"title":"Circ_0005615 enhances multiple myeloma progression through interaction with EIF4A3 to regulate MAP3K4 m6A modification mediated by ALKBH5","authors":"Kai Zhu , Fengquan Gou , Ziwen Zhao , Ke Xu , Jian Song , Hongyi Jiang , Feng Zhang , Yanli Yang , Jiajia Li","doi":"10.1016/j.leukres.2024.107451","DOIUrl":"10.1016/j.leukres.2024.107451","url":null,"abstract":"<div><h3>Background</h3><p>Circular RNAs (circRNAs) are associated with development and progression of multiple myeloma (MM). However, the role and mechanism of circ_0005615 in MM have not been elucidated.</p></div><div><h3>Methods</h3><p>Circ_0005615 was determined by GEO database. quantitative RT-PCR was performed to confirm the expression of circ_0005615 in peripheral blood of MM patients and MM cells. The roles of circ_0005615 in MM were analyzed using CCK8, transwell invasion, cell apoptosis and tumor xenograft experiments. Bioinformatics tools, RIP and RNA pull down assays were conducted to explore the downstream of circ_0005615. Furthermore, the mechanism was investigated by quantitative RT-PCR, western blot, dot blot and meRIP-PCR assays.</p></div><div><h3>Results</h3><p>Circ_0005615 was upregulated in MM. Overexpression of circ_0005615 promoted cell viability and invasion, and suppressed apoptosis <em>in vitro</em>, which were opposite when circ_0005615 was knockdowned. Mechanistically, EIF4A3, a RNA-binding protein (RBP), could directly bind to circ_0005615 and ALKBH5, where ALKBH5 could directly combine with MAP3K4, forming a circ_0005615- EIF4A3-ALKBH5-MAP3K4 module. Furthermore, circ_0005615 overexpression increased m6A methylation of MAP3K4 by inhibiting ALKBH5, leading to decreased MAP3K4. Further functional experiments indicated that ALKBH5 overexpression weakened the promoting roles of circ_0005615 overexpression in MAP3K4 m6A methylation and tumor progression in MM. The above functions and mechanism were also verified <em>in vivo</em>.</p></div><div><h3>Conclusions</h3><p>Elevated circ_0005615 decreased MAP3K4 mediated by ALKBH5 through interacting with EIF4A3, thereby accelerating MM progression. Circ_0005615 might be a promising biomarker and target of MM.</p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"141 ","pages":"Article 107451"},"PeriodicalIF":2.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139663308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0